RxDoctor Payments Data

Annette Hall

Nurse Practitioner · Springfield, OHNPI 1235763012

Payments from drug & device makers

$3,343in general payments, 2019–2025

Across 149 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$534
  • Jazz Pharmaceuticals Inc.$461
  • Sanofi$363
  • Sanofi-aventis U.S. LLC$195
  • Regeneron Healthcare Solutions, Inc.$137
  • plus $638 from 16 others

What the payments were for

  • Food & beverage$2,93288%
  • Education$41112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,343 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$18,898
Medicare patients
118
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter189$160,113
Breztri AerosphereBudesonide/Glycopyr/Formoterol96$70,775
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr85$47,187
Spiriva RespimatTiotropium Bromide57$39,851
Breo ElliptaFluticasone/Vilanterol73$34,883
Bevespi AerosphereGlycopyrrolate/Formoterol Fum39$19,111
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$17,699
SymbicortBudesonide/Formoterol Fumarate54$16,683
Incruse ElliptaUmeclidinium Bromide28$10,874
Albuterol Sulfate HfaAlbuterol Sulfate381$9,064
DuleraMometasone/Formoterol14$7,922
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,616
Fluticasone Propionate HfaFluticasone Propionate11$3,503
Montelukast Sodium133$1,484
Fluticasone Propionate25$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$534$253,058375 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$1,016$106,569189 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$13$57,55086 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →